News Can Pear bud again? Ex-CEO McCann bids for assets Digital therapeutics (DTx) company Pear Therapeutics may be heading for a new lease of life, if a plan by former chief executive Corey McCann pays off.
News UK project addresses capacity issue in CGT manufacturing A UK consortium has been set up to tackle a major issue in the development of cell and gene therapies (CGT) – a lack of manufacturing capacity.
Market Access The value of a partner, globally and locally A new podcast looks at recent trends related to drug approvals, as well as challenges and opportunities both small and large pharma companies face